By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Novavax (NVAX) shares added ~5% in the premarket on Tuesday after the COVID-19 vaccine maker reached a licensing deal with ...

Novavax (NVAX) has become a focus for investors after signing a license agreement that allows Pfizer to use its Matrix-M ...

Novavax ‌said on ‌Tuesday it was ⁠entering ‌into a ‍licensing agreement with ​Pfizer ‌to develop vaccine products ⁠for ...

Gaithersburg’s Novavax has struck a deal to give Pfizer the rights to its adjuvant technology — for a potential $530 million ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments.

Shares of US biotech Novavax were up 9% at $8.72 by midday on Tuesday, after it revealed it has entered into a license ...

Long-term data suggest Moderna’s personalized melanoma shot provides “durable tumor control,” one analyst said. Elsewhere, ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...